Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2009 Feb;23(1):69-78, viii. doi: 10.1016/j.hoc.2008.11.006.

Gastrointestinal stromal tumor: a clinical overview.

Author information

1
Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

Abstract

Gastrointestinal stromal tumor (GIST) is a disease that was poorly understood historically. In the last decade, it has undergone a major transformation, sparked by the landmark discovery of the central role of activating KIT mutations in its pathogenesis and recognition of KIT protein expression (CD 117) as a reliable diagnostic marker of disease. The introduction and subsequent US Food and Drug administration approval of imatinib mesylate in the treatment of metastatic or unresectable GIST in February 1, 2002 has thrust this hitherto little known disease into the center stage of oncology, and GIST has served as a model for rationally designed drug trials in the field of cancer therapeutics since.

PMID:
19248971
DOI:
10.1016/j.hoc.2008.11.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center